Nickan Research Institute Journal of Parathyroid Disease 2345-6558 12 1 2024 01 01 Clinical administration of cinacalcet in parathyroid diseases e11256 e11256 10.34172/jpd.2024.11256 EN Azadeh Khayyat https://orcid.org/0000-0002-1867-1609 Mohammad Ali Esmaeil Pour https://orcid.org/0000-0002-0393-3928 EDITORIAL 10.34172/jpd.2024.11256 2023 12 20 2024 02 10 Cinacalcet has emerged as an effective therapeutic option for the management of secondary hyperparathyroidism (SHPT) and chronic kidney disease-mineral and bone disorder (CKD-MBD). Through its modulation of the calcium-sensing receptor (CaSR), cinacalcet demonstrates considerable clinical benefits in maintaining parathyroid hormone and serum calcium levels within target ranges. It offers a valuable addition to the available treatment options for patients with these conditions. Cinacalcet binds to the CaSR on parathyroid cells, increasing its sensitivity to extracellular calcium. This results in decreased parathyroid hormone (PTH; parathormone), release through inhibition of intracellular signaling pathways involved in PTH synthesis and secretion. Cinacalcet also indirectly reduces serum calcium and phosphorus levels by suppressing PTH-mediated bone resorption and enhancing renal phosphate excretion.